The Online Investor
Zai Lab Ltd (ZLAB)

Zai Lab is a holding company. Through its subsidiaries, Co. is a commercial-stage biopharmaceutical company based in China and the United States focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need in the China and global markets, including in the fields of oncology, infectious and autoimmune diseases. Co.'s eight clinical stage products consist of seven late-stage drug candidates. These drug candidates are: Niraparib (ZEJULA), Optune (Tumor-Treating Fields), Margetuximab, MGD013, Bemarituzumab, Brivanib, Omadacycline and ETX2514.
Company Name: 
Zai Lab Ltd
Website: 
www.zailaboratory.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ZLAB: 
21
Total Market Value Held by ETFs: 
$114.20M
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Zai Lab Ltd (ZLAB) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.